Dr Nigam agrees to doubling slick NW6/NW7

[cocacola]

You are, without a doubt, the dumbest frequent poster on these boards.

This guy is hilarious actually

[TO YOUNG TO RETIRE]

because some upolite people here started talking rude to him i believe....but Dr we are still people that respect you here and need to hear from you....

Nigam is dead?

Why not write more updates. First always wrote to talk about anything, now that should give conclusive evidence there has never ...

[ccmethinning]

This guy is hilarious actually

The guy even has a grammatical error in his own username...

[UK_]

I find it funny how he talks... then has the quote underneath.

The guy even has a grammatical error in his own username...

[greatjob!]

The guy even has a grammatical error in his own username...

Probably because English is his second (or third or tenth) language, which no doubt contributes to your perception of him being "without a doubt, the dumbest frequent poster on these boards."

I'm sure if you posted on a forum that was published in a language that you weren't completely familiar with, you would also sound quite dumb to native or fluent speakers.

[UK_]

I cant believe how Replicel hasnt started Phase II yet - didnt they say they were going to start mid-2013?

If all goes to plan they will have only completed phase II by 2017 - what a JOKE!

[crafter]

I cant believe how Replicel hasnt started Phase II yet - didnt they say they were going to start mid-2013?

If all goes to plan they will have only completed phase II by 2017 - what a JOKE!

the longer they spread out their research (that they know is not that effective and wont go to market) the longer they keep their jobs.

Same with Aderans. Histogen seem to be the only ones making progress.

Deressing times.

[greatjob!]

the longer they spread out their research (that they know is not that effective and wont go to market) the longer they keep their jobs.

This is a completely false statement. When you work for a start-up biotech company you make very little in terms of salary, most compensation is paid out in ownership and stock options. The incentive in working for a biotech start-up is to develop something that can be sold to big pharma and cash in a big pay day. What your claiming is the exact opposite of what the reality is in the industry.

[Arashi]

This is a completely false statement. When you work for a start-up biotech company you make very little in terms of salary, most compensation is paid out in ownership and stock options. The incentive in working for a biotech start-up is to develop something that can be sold to big pharma and cash in a big pay day. What your claiming is the exact opposite of what the reality is in the industry.

You guys are both right. Yes, of course the ultimate goal is to hit the homerun and sell it to a big pharma for example. But as long as a startup can convince investors to put more money into their company, they have an incentive to keep muddling on even when they know they will never get to something. You see the same thing in some public traded companies. They keep offering shares, stock price tanks and when it gets too low, they reverse split. Meanwhile management keeps paying themselves good salaries, plus, more importantly, they keep giving themselves stockbonuses and sell those to the market.

[JDW]

Alright, just dropping in for the update. Has this started yet? The doubling procedures?

[Arashi]

Alright, just dropping in for the update. Has this started yet? The doubling procedures?

Supposedly he'll start with Thane this monday.

[TO YOUNG TO RETIRE]

i suppose we will get pics....

Supposedly he'll start with Thane this monday.

[Artha]

Supposedly he'll start with Thane this monday.

And from that it will take a full year to know if its safe!

[TO YOUNG TO RETIRE]

what do you mean by that? it is safe already

And from that it will take a full year to know if its safe!

[UK_]

You guys are both right. Yes, of course the ultimate goal is to hit the homerun and sell it to a big pharma for example. But as long as a startup can convince investors to put more money into their company, they have an incentive to keep muddling on even when they know they will never get to something. You see the same thing in some public traded companies. They keep offering shares, stock price tanks and when it gets too low, they reverse split. Meanwhile management keeps paying themselves good salaries, plus, more importantly, they keep giving themselves stockbonuses and sell those to the market.

Personally, I know we havent seen much evidence for our own eyes, but I think Nigam has really shook up the hair transplant sector - the fact that Dr Mwamba an IAHRS surgeon went to see and LEARN his technique is partial evidence of this... even Dr Cole was interested, I bet behind the scenes a lot of surgeons are following what Nigam is doing.